News
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Zenchent®
Under a supply agreement between Warner Chilcott and Watson Pharma, Inc., Watson has launched Zenchent® (norethindrone and ethinyl estradiol tablets USP).
Warner Chilcott Company, Inc. and Watson Pharmaceuticals, Inc. announced today that under a supply agreement between Warner Chilcott and Watson Pharma, Inc., Watson has launched Zenchent® (norethindrone and ethinyl estradiol tablets USP), the generic version of Warner Chilcott's oral contraceptive Ovcon 35®.
Under the terms of the agreement, Warner Chilcott will supply Zenchent® to Watson Pharma, which will market, sell and distribute the generic product in the United States. Warner Chilcott will receive a share of the profits from Watson's sales of the generic product in the U.S. market. Further details on the agreement have not been disclosed.
Warner Chilcott Company, Inc. is a subsidiary of Warner Chilcott Limited.WCRX - News)
Watson Pharma, Inc. is a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI - News).